Search results

Order by most recent / most popular / relevance

Results: 1-4 of 4

Teva Canada Innovation v. Attorney General of Canada

Borden Ladner Gervais LLP
-
Canada
-
May 8 2013

The Patented Medicine Prices Review Board (the PMPRB) ordered Teva to pay the Crown approximately $2.4 million for selling its product at an

Northern exposure?

Gowling Lafleur Henderson LLP
-
Canada, USA
-
April 4 2013

Davit Akman and John Norman suggest that a recently commenced investigation into alleged "product switching" and statements by the Interim

Supreme Court of Canada holds that PMPRB has jurisdiction over sales made ''into Canada'' pursuant to the special access program (Thalomid)

Norton Rose Canada LLP
-
Canada
-
January 20 2011

On January 20, 2011, the Supreme Court of Canada dismissed an appeal by Celgene Corporation ("Celgene") and held that the Patented Medicine Prices Review Board ("Board") has jurisdiction to regulate the price of patented medicines that are sold into Canada pursuant to the Health Canada Special Access Program as part of its "consumer protection" mandate

BC pharmaceutical policy reforms

Borden Ladner Gervais LLP
-
Canada
-
July 16 2010

Following the lead of Ontario, British Columbia has taken steps to further reform its provincial policy with respect to pharmaceuticals

Search results

Teva Canada Innovation v. Attorney General of Canada

Northern exposure?

Supreme Court of Canada holds that PMPRB has jurisdiction over sales made ''into Canada'' pursuant to the special access program (Thalomid)

BC pharmaceutical policy reforms

Current Search

Suggested Facets

Author

Firm Name